Showing results (91-100 of 321) with videos related to

Sort By:
Pageof 33
British Journal of Cancer|April 16, 2002
ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft modelK J Williams, B A Telfer, I J Stratford, et al.
Bioorganic & Medicinal Chemistry Letters|April 2, 2010
Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2K A Nolan, M P Humphries, R A Bryce, et al.
International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine|January 1, 1983
Abnormal radiosensitizing and cytotoxic properties of ortho-substituted nitroimidazolesI J Stratford, S Hoe, G E Adams, et al.
The Journal of Physiology|May 22, 1998
Synaptic interactions between smooth and spiny neurones in layer 4 of cat visual cortex in vitroK Tarczy-Hornoch, K A Martin, J J Jack, et al.
British Journal of Cancer|December 1, 1982
In vitro cytotoxic drug sensitivity testing of human tumour xenografts grown as multicellular tumour spheroidsA C Jones, I J Stratford, P A Wilson, et al.
Bioorganic & Medicinal Chemistry Letters|October 3, 2006
In silico identification and biochemical characterization of novel inhibitors of NQO1Karen A Nolan, David J Timson, Ian J Stratford, et al.
Biochemical Pharmacology|August 4, 1992
The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase?N Robertson, I J Stratford, S Houlbrook, et al.
Anti-Cancer Drugs|April 20, 2004
The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell linesJ Y Kim, A V Patterson, I J Stratford, et al.
Proceedings. Biological Sciences|October 23, 1995
The variance of successive peaks in synaptic amplitude histograms: effects of inter-site differences in quantal sizeL M Wahl, K J Stratford, A U Larkman, et al.
Molecular Pharmacology|September 17, 2008
Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1)Chao Yan, Jadwiga K Kepa, David Siegel, et al.
Pageof 33